On January 9, 2026, PDS Biotechnology Corp announced a protocol amendment for its Phase 3 VERSATILE-003 trial, aiming for earlier evaluation of the primary endpoint which may lead to accelerated approval for PDS0101, while median overall survival remains a key endpoint for full approval. This amendment could enhance the chances of receiving regulatory approval sooner.